Tuis4507 ā¢ TYO
add
Shionogi & Co Ltd
Vorige sluiting
Ā„2Ā 144,00
Dagwisseling
Ā„2Ā 110,00 - Ā„2Ā 152,00
Jaarwisseling
Ā„1Ā 944,66 - Ā„2Ā 712,33
Markkapitalisasie
1,87Ā bn JPY
Gemiddelde volume
2,60Ā m
P/V-verhouding
11,76
Dividend-opbrengs
2,67%
PrimĆŖre beurs
TYO
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
(JPY) | Sep. 2024info | J/J-verandering |
---|---|---|
Inkomste | 116,38Ā mjd | -4,00% |
Bedryfskoste | 52,93Ā mjd | -3,66% |
Netto inkomste | 52,50Ā mjd | 9,30% |
Netto winsgrens | 45,11 | 13,86% |
Wins per aandeel | ā | ā |
EBITDA | 53,13Ā mjd | -5,14% |
Effektiewe belastingkoers | 8,28% | ā |
Balansstaat
Totale bates
Totale aanspreeklikheid
(JPY) | Sep. 2024info | J/J-verandering |
---|---|---|
Kontant en korttermynbeleggings | 303,40Ā mjd | 20,22% |
Totale bates | 1,46Ā bn | 3,34% |
Totale aanspreeklikheid | 145,93Ā mjd | -18,09% |
Totale ekwiteit | 1,31Ā bn | ā |
Uitstaande aandele | 850,69Ā m | ā |
Prys om te bespreek | 1,28 | ā |
Opbrengs op bates | 8,22% | ā |
Opbrengs op kapitaal | 9,10% | ā |
Kontantvloei
Netto kontantverandering
(JPY) | Sep. 2024info | J/J-verandering |
---|---|---|
Netto inkomste | 52,50Ā mjd | 9,30% |
Kontant van bedrywe | 45,30Ā mjd | 220,14% |
Kontant van beleggings | -17,63Ā mjd | 47,30% |
Kontant van finansiering | -1,11Ā mjd | 94,50% |
Netto kontantverandering | 21,45Ā mjd | 158,43% |
Beskikbare kontantvloei | 8,02Ā mjd | 135,46% |
Meer oor
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana.
Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines.
In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan.
Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV.
The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index.
In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m. Wikipedia
Gestig
1878
Hoofkwartier
Webwerf
Werknemers
4Ā 959